In order to tell which way a stock is trending, the stock’s share price should be compared to its moving average. The stock will be uptrending if it is being traded above its moving averages and downtrending if it is being traded below. The stock stands -8.00% away from its 50-day simple moving average and -10.07% away from the 200-day average. The price currently stands at $7.73.

An uptrend occurs when a stock makes trends higher due to consecutive higher highs and higher lows over a period of time. Each relative high is above the previous high while each relative low is higher than the previous low. An uptrend stays a trend until the series of higher highs and higher lows has ended. A downside movement of a rising trend line should be considered to be a sell signal, and is usually an indication that the uptrend will end soon. The uptrend is considered to be finished whenever a lower high or lower low is formed.

Recent Performance

Let’s take a look at how the stock has been performing recently. Over the past twelve months, Pacific Biosciences of California, Inc. (NASDAQ:PACB)‘s stock was -41.28%. -8.21% over the last quarter, and -20.02% for the past six months.

Over the past 50 days, Pacific Biosciences of California, Inc. stock was -18.63% off of the high and 16.94% removed from the low. Their 52-Week High and Low are noted here. -44.79% (High), 16.94%, (Low).

The consensus analysts recommendation at this point stands at 1.90 on this stock. This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. The Street has a 11.67 target price on the shares for the next 12-18 months.

The information provided on this website is for individual use only and should be considered strictly informational in nature. The article is not advice, and should not be treated as such. We are in no way responsible for any investment loss or damages. All content in our articles is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities.

Viewers should always consult with a licensed securities professional before purchasing or selling any securities of companies profiled or discussed in our articles. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. We make no recommendation that the securities of the companies profiled or discussed in on our website should be purchased, sold or held by investors.